GF Fund Management
ELVN icon

GF Fund Management’s Enliven Therapeutics ELVN Stock Holding History

GF Fund Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$62.8K Buy
1,369
+111
+9% +$6.05K ﹤0.01% 369
2026
Q2 		$63.8K Sell
1,258
-75
-6% -$3.18K ﹤0.01% 368
2026
Q1 		$52.3K Buy
1,333
+168
+14% +$4.65K ﹤0.01% 393
2025
Q4 		$17.9K Sell
1,165
-109
-9% -$2.17K ﹤0.01% 519
2025
Q3 		$26.1K Buy
1,274
+23
+2% +$464 ﹤0.01% 459
2025
Q2 		$25.1K Hold
1,251
– – ﹤0.01% 477
2025
Q1 		$24.6K Buy
1,251
+225
+22% +$4.84K ﹤0.01% 479
2024
Q4 		$23.1K Buy
+1,026
New +$26.6K ﹤0.01% 460

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

GF Fund Management's ELVN Position: Q3 2026 in Review

GF Fund Management increased its Enliven Therapeutics (ELVN) stake by 8.8% in Q3 2026, buying an estimated $6.05K and bringing the position to 1,369 shares worth $62.8K. The position accounts for ﹤0.01% of the portfolio, ranked #369.

GF Fund Management first reported a position in ELVN in Q4 2024 and has held it in 8 quarters since. The position peaked at $63.8K in Q2 2026. 133 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.

  • GF Fund Management held 1,369 shares of Enliven Therapeutics worth $62.8K as of Q3 2026.
  • GF Fund Management bought 111 Enliven Therapeutics shares in Q3 2026, an estimated $6.05K.
  • Enliven Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #369 holding.
  • GF Fund Management first reported a position in Enliven Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • GF Fund Management's Enliven Therapeutics position peaked at $63.8K in Q2 2026.
  • 133 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.